DNMT3A mutations in Chinese childhood acute myeloid leukemia
Open Access
- 1 August 2017
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Medicine
- Vol. 96 (31), e7620
- https://doi.org/10.1097/md.0000000000007620
Abstract
DNA methyltransferase 3A (DNMT3A) mutations have been found in approximately 20% of adult acute myeloid leukemia (AML) patients and in 0% to 1.4% of children with AML, and the hotspots of mutations are mainly located in the catalytic methyltransferase domain, hereinto, mutation R882 accounts for 60%. Although the negative effect of DNMT3AR882 on treatment outcome is well known, the prognostic significance of other DNMT3A mutations in AML is still unclear. Here, we tried to determine the incidence and prognostic significance of DNMT3A mutations in a large cohort in Chinese childhood AML. We detected the mutations in DNMT3A exon 23 by polymerase chain reaction and direct sequencing in 342 children with AML (0–16 years old) from January 2005 to June 2013, treated on BCH-2003 AML protocol. The correlation of DNMT3A mutations with clinical characteristics, fusion genes, other molecular anomalies (FLT3 internal tandem duplication [FLT3-ITD], Nucleophosmin 1, C-KIT (KIT proto-oncogene receptor tyrosine kinase), and Wilms tumor 1 mutations), and treatment outcome were analyzed. DNMT3A mutations were detected in 4 out of 342 (1.2%) patients. Two patients were PML-RARA positive and 1 patient was FLT3-ITD positive. The mutations in coding sequences included S892S, V912A, R885G, and Q886R. Furthermore, there was 1 intronic mutation (c.2739+55A>C) found in 1 patient. No association of DNMT3A mutations with common clinical features was found. Two patients with DNMT3A mutations died of relapse or complications during treatment. One patient gave up treatment due to remission induction failure in day 33. Only 1 patient achieved continuous complete remission. DNMT3A mutations were rare in Chinese children with AML including PML-RARA positive APL. The mutation positions were different from the hotspots reported in adult AML. DNMT3A mutations may have adverse impact on prognosis of children with AML.Keywords
This publication has 35 references indexed in Scilit:
- Mutational Cooperativity Linked to Combinatorial Epigenetic Gain of Function in Acute Myeloid LeukemiaCancer Cell, 2015
- DNMT3Amutations and prognostic significance in childhood acute lymphoblastic leukemiaLeukemia & Lymphoma, 2014
- New Insights in AML Biology From Genomic AnalysisSeminars in Hematology, 2014
- DNMT3A R882 mutations in patients with cytogenetically normal acute myeloid leukemia and myelodysplastic syndromeBlood Cells, Molecules, and Diseases, 2014
- The R882H DNMT3A Mutation Associated with AML Dominantly Inhibits Wild-Type DNMT3A by Blocking Its Ability to Form Active TetramersCancer Cell, 2014
- Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French AssociationLeukemia, 2012
- DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implicationsBlood, 2012
- Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemiaEuropean Journal of Haematology, 2011
- Leukemic mutations in the methylation‐associated genes DNMT3A and IDH2 are rare events in pediatric AML: A report from the Children's Oncology GroupPediatric Blood & Cancer, 2011
- DNMT3AMutations in Acute Myeloid LeukemiaThe New England Journal of Medicine, 2010